<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031144</url>
  </required_header>
  <id_info>
    <org_study_id>KUMC 2019-05-008</org_study_id>
    <nct_id>NCT04031144</nct_id>
  </id_info>
  <brief_title>Ultrafiltration on Coagulation Function in Cardiac Surgery</brief_title>
  <official_title>Effect of Ultrafiltration Before Weaning From Cardiopulmonary Bypass on Post-bypass Coagulation Function in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of microfiltration, which is usually employed for reducing free water
      at the end of cardiopulmonary bypass (CPB), on post-CPB coagulation profile in patients
      undergoing cardiac surgery
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal clot formation (MCF) in rotational thromboelastometry, EXTEM</measure>
    <time_frame>15 min after weaning from cardiopulmonary bypass</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clotting time (CT) in rotational thromboelastometry, EXTEM</measure>
    <time_frame>15 min after weaning from cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal clot formation at 8 min in rotational thromboelastometry, FIBTEM</measure>
    <time_frame>15 min after weaning from cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of lysis in rotational thromboelastometry, EXTEM</measure>
    <time_frame>15 min after weaning from cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>15 min after weaning from cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cardiac Valve Disease</condition>
  <arm_group>
    <arm_group_label>Ultrafiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrafiltration is applied at the end of cardiopulmonary bypass procedure. The amount of filtration volume is determined by an attending perfuionist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrafiltration</intervention_name>
    <description>At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components</description>
    <arm_group_label>Ultrafiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing elective cardiac surgery

        Exclusion Criteria:

          -  transfusion of RBC&gt; 3 units, total ultrafiltration volume &lt; 250 ml, hyperfibrinolysis
             before ultrafiltration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tae-Yop Kim</last_name>
    <phone>82-2-2030-5445</phone>
    <email>taeyop@gmail.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

